Cargando…

Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

BACKGROUND: The inhibitory CTLA-4 molecule is a crucial regulator of immune responses and a target for therapeutic intervention in both autoimmunity and cancer. In particular, CTLA-4 is important in controlling antigen-specific immunity, including responses to autoantigens associated with autoimmune...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahal, Lekh N., Basu, Neil, Youssef, Hazem, Khanolkar, Rahul C., Barker, Robert N., Erwig, Lars P., Ward, Frank J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973056/
https://www.ncbi.nlm.nih.gov/pubmed/27487771
http://dx.doi.org/10.1186/s13075-016-1075-1
_version_ 1782446342884294656
author Dahal, Lekh N.
Basu, Neil
Youssef, Hazem
Khanolkar, Rahul C.
Barker, Robert N.
Erwig, Lars P.
Ward, Frank J.
author_facet Dahal, Lekh N.
Basu, Neil
Youssef, Hazem
Khanolkar, Rahul C.
Barker, Robert N.
Erwig, Lars P.
Ward, Frank J.
author_sort Dahal, Lekh N.
collection PubMed
description BACKGROUND: The inhibitory CTLA-4 molecule is a crucial regulator of immune responses and a target for therapeutic intervention in both autoimmunity and cancer. In particular, CTLA-4 is important in controlling antigen-specific immunity, including responses to autoantigens associated with autoimmune disease. Here, we investigate cytokine responses to a range of lupus-associated autoantigens and assess whether the alternatively spliced isoform of CTLA-4, soluble CTLA-4 (sCTLA-4), contributes to immune regulation of autoantigen-specific immunity in systemic lupus erythematosus (SLE). METHODS: The cell culture supernatant production of sCTLA-4 as well as the cytokines IL-10, IFN-γ, and IL-17 from peripheral blood mononuclear cells (PBMC) from lupus patients and age- and sex-matched healthy volunteer donors were measured in response to previously identified histone and small nuclear ribonucleoprotein (snRNP) autoantigen-derived peptides (H3(91-105), H4(71-93), and U170K(131-151)) by ELISA. We also examined the functional contribution of sCTLA-4 to immune regulation in the context of these autoantigenic peptides following blockade of sCTLA-4 with a selective anti-sCTLA-4 monoclonal antibody, JMW-3B3. RESULTS: We identified responses to autoantigenic peptides, which revealed qualitative differences in cytokine (IL-10, IL-17, and IFN-γ) profiles between SLE patients and healthy donors. PBMC from healthy donors responded to each of the lupus peptides by secreting IFN-γ and IL-17, but PBMC from SLE patients produced IL-10. Although we did not observe differences in the levels of serum or PBMC culture supernatant sCTLA-4 in either cohort, blockade of sCTLA-4 in PBMC cultures responding to antigen enhanced the cytokine profiles associated with each group. CONCLUSION: The results show that lupus autoantigen-derived peptides display varied immunogenicity in lupus versus healthy volunteer donors, while sCTLA-4 acts to regulate the T-cell activity independently of response profile. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1075-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4973056
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49730562016-08-05 Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus Dahal, Lekh N. Basu, Neil Youssef, Hazem Khanolkar, Rahul C. Barker, Robert N. Erwig, Lars P. Ward, Frank J. Arthritis Res Ther Research Article BACKGROUND: The inhibitory CTLA-4 molecule is a crucial regulator of immune responses and a target for therapeutic intervention in both autoimmunity and cancer. In particular, CTLA-4 is important in controlling antigen-specific immunity, including responses to autoantigens associated with autoimmune disease. Here, we investigate cytokine responses to a range of lupus-associated autoantigens and assess whether the alternatively spliced isoform of CTLA-4, soluble CTLA-4 (sCTLA-4), contributes to immune regulation of autoantigen-specific immunity in systemic lupus erythematosus (SLE). METHODS: The cell culture supernatant production of sCTLA-4 as well as the cytokines IL-10, IFN-γ, and IL-17 from peripheral blood mononuclear cells (PBMC) from lupus patients and age- and sex-matched healthy volunteer donors were measured in response to previously identified histone and small nuclear ribonucleoprotein (snRNP) autoantigen-derived peptides (H3(91-105), H4(71-93), and U170K(131-151)) by ELISA. We also examined the functional contribution of sCTLA-4 to immune regulation in the context of these autoantigenic peptides following blockade of sCTLA-4 with a selective anti-sCTLA-4 monoclonal antibody, JMW-3B3. RESULTS: We identified responses to autoantigenic peptides, which revealed qualitative differences in cytokine (IL-10, IL-17, and IFN-γ) profiles between SLE patients and healthy donors. PBMC from healthy donors responded to each of the lupus peptides by secreting IFN-γ and IL-17, but PBMC from SLE patients produced IL-10. Although we did not observe differences in the levels of serum or PBMC culture supernatant sCTLA-4 in either cohort, blockade of sCTLA-4 in PBMC cultures responding to antigen enhanced the cytokine profiles associated with each group. CONCLUSION: The results show that lupus autoantigen-derived peptides display varied immunogenicity in lupus versus healthy volunteer donors, while sCTLA-4 acts to regulate the T-cell activity independently of response profile. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1075-1) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-04 2016 /pmc/articles/PMC4973056/ /pubmed/27487771 http://dx.doi.org/10.1186/s13075-016-1075-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Dahal, Lekh N.
Basu, Neil
Youssef, Hazem
Khanolkar, Rahul C.
Barker, Robert N.
Erwig, Lars P.
Ward, Frank J.
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
title Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
title_full Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
title_fullStr Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
title_full_unstemmed Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
title_short Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
title_sort immunoregulatory soluble ctla-4 modifies effector t-cell responses in systemic lupus erythematosus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973056/
https://www.ncbi.nlm.nih.gov/pubmed/27487771
http://dx.doi.org/10.1186/s13075-016-1075-1
work_keys_str_mv AT dahallekhn immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus
AT basuneil immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus
AT youssefhazem immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus
AT khanolkarrahulc immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus
AT barkerrobertn immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus
AT erwiglarsp immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus
AT wardfrankj immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus